Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial

INTRODUCTION: Insulin degludec (IDeg) is an ultra‐long‐acting basal insulin with a consistent action profile of >42 h. This trial compared the efficacy and safety of IDeg with insulin glargine (IGlar) in insulin‐naïve Asian patients with type 2 diabetes. MATERIALS AND METHODS: In this multination...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Onishi, Yukiko, Iwamoto, Yasuhiko, Yoo, Soon Jib, Clauson, Per, Tamer, Søren C, Park, Sungwoo
Materialtyp: Online Artikel Text
Språk:English
Publicerad: Wiley-Blackwell 2013
Ämnen:
Articles
Länkar:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020256/
https://www.ncbi.nlm.nih.gov/pubmed/24843715
http://dx.doi.org/10.1111/jdi.12102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020256/
https://www.ncbi.nlm.nih.gov/pubmed/24843715
http://dx.doi.org/10.1111/jdi.12102

Liknande verk